Your session is about to expire
← Back to Search
Olaparib + Abiraterone for Prostate Cancer
Study Summary
This trial is testing the safety and efficacy of adding olaparib to abiraterone for the treatment of metastatic castration-resistant prostate cancer.
- Metastatic Castration Resistant Prostate Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received immunotherapy or radium-223 for treating advanced prostate cancer in the past.You have taken strong medications that can either slow down or speed up the breakdown of other drugs in your body within the past 2 weeks (3 weeks for St. John's Wort).You have tumors in your spine or brain, but if they are not causing symptoms, treated and stable for at least 4 weeks without needing steroids, you can still participate in the study.You have already received more than two rounds of chemotherapy for advanced prostate cancer.You should not have any ongoing side effects from previous treatments that are worse than a moderate level, except for hair loss or side effects caused by certain medications.You have had another type of cancer in the past 5 years, except for non-melanoma skin cancer or other solid tumors that have been successfully treated and have not returned for at least 5 years.I'm sorry, but I need more information to rewrite this criterion. Could you please provide the specific treatments that are listed in the original criterion?You have received a medicine called a PARP inhibitor, like olaparib, in the past.You have received a bone marrow transplant from someone else in the past.You have ongoing problems with severe nausea and vomiting or chronic gastrointestinal diseases. You also have difficulty swallowing the study medication or have had a significant portion of your bowel removed, which could affect how your body absorbs the medication.
- Group 1: Olaparib
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the protocol for this experiment limit participation to individuals under 80 years of age?
"This study will only accept patients between the ages of 18 and 130. Separately, there are 162 trials for minors and 1767 studies open to those over 65 years old."
Has Olaparib been granted authorization by the FDA?
"For the safety of Olaparib, our team has assigned a score of 2. This is because Phase 2 trials have provided some evidence that this drug is safe, yet there are no studies confirming its efficacy."
What aims are investigators hoping to accomplish with this experiment?
"The primary purpose of the trial is to assess how many patients experience dose-limiting toxicities, while secondary objectives include determining the percentage of patients with PSA responses, assessing anti-tumour activity through CTC levels and calculating abiraterone tmax,ss following multiple dosing."
What therapeutic applications does Olaparib have?
"Olaparib is primarily utilized for treating multiple sclerosis, but it can be prescribed to manage a range of other medical issues including ulcerative colitis, varicella-zoster virus acute retinal necrosis and brain."
Are there currently any vacancies for this medical research project?
"According to the data supplied by clinicaltrials.gov, this medical trial has ceased recruiting patients after being initially posted on April 1st 2014 and last updated October 7th 2022. Fortunately there are 1852 other trials with open enrolment at present."
Do I meet the qualifications necessary to participate in this medical experiment?
"This medical trial seeks 158 male participants aged 18 to 130 who have undergone castration and are diagnosed with prostate cancer. To be eligible, applicants must exhibit an Eastern Cooperative Oncology Group performance status of 0-2 over the last fortnight, possess a life expectancy ≥12 weeks, remain on stable concomitant medications (except for bisphosphonates, denosumab and corticosteroids) , agree to follow protocol instructions throughout their participation in the study including undergoing treatment & examinations and completing PRO instruments., For those selected to partake in the randomized phase only, prior docetaxel chemotherapy is required. However patients who discontinued"
What other investigations have been conducted relative to Olaparib?
"Currently, there are 599 active trials investigating the impact of Olaparib. A significant portion (145) have progressed to Phase 3 and Duarte, California is host to a major concentration of studies. In total, 26594 sites around the world are researching this drug's potential applications."
What is the participant capacity for this research endeavor?
"As of this moment, no further participants are being accepted into the trial. This study was posted on April 1st 2014 and revised October 7th 2022. If you're seeking out other studies related to castration there are 1253 active trials while Olaparib is featured in 599 clinical studies currently recruiting patients."
What is the current number of hospitals conducting this experiment?
"At the present time, 5 sites are offering this trial. Patients may choose from San Diego, London, and Greenfield Park along with other nearby centres to reduce travel-related burden associated with participation."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger